← All trials
NCT06380153
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 7, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Apr 23, 2024
- Last posted
- Jun 25, 2024
- Enrollment
- 24
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hemay Pharmaceutical PTY. LTD.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.